Description: Amylyx Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada. The company is developing AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid for the treatment of ALS and other neurodegenerative diseases. It is also developing products for Wolfram syndrome and Alzheimer's diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Home Page: amylyx.com
AMLX Technical Analysis
43 Thorndike Street
Cambridge,
MA
02141
United States
Phone:
617 682 0917
Officers
| Name | Title |
|---|---|
| Mr. Joshua B. Cohen | Co-Founder, Co-CEO & Director |
| Mr. Justin B. Klee | Co-Founder, Co-CEO & Director |
| Mr. James M. Frates M.B.A. | Chief Financial Officer |
| Ms. Margaret M. Olinger M.B.A | Global Head of Commercial & Chief Commercial Officer |
| Mr. Tom Holmes | Chief Technical Operations Officer |
| Ms. Gina M. Mazzariello | Chief Legal Officer & Gen. Counsel |
| Ms. Shauna Horvath | Head of Global Marketing |
| Ms. Debra L. Canner | Global Head of HR & CHRO |
| Dr. Patrick D. Yeramian M.D., MBA, Ph.D. | Global Head of Clinical R&D and Chief Medical Officer |
| Mr. Chris Aiello | Head of Canada & GM |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 16.3998 |
| Price-to-Sales TTM: | 6725.4844 |
| IPO Date: | 2022-01-07 |
| Fiscal Year End: | December |
| Full Time Employees: | 237 |